Sarasota, Fla. – October 07, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) reported that its Bisphosphocin compound Nu-8, delivered intravesically to rodents infected with E. coli, achieved up to 97% inhibition of bacterial growth using a 10% solution, against no effect in a vehicle control group.

Sarasota, Fla. – September 11, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.

Sarasota, Fla. – September 11, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.